Program Pipeline
iOmx is driving a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity and multimodal mechanisms of action, iOmx is creating potential new backbone therapies in a modality-open fashion. By applying its comprehensive drug discovery & development expertise and in collaboration with Pharma partners, iOmx is committed to shaping the future of cancer therapy.
Program |
Target & Modality |
Indications |
Discovery |
Lead ID |
Lead Optimisation |
IND Enabling |
Clinical Ph I |
Clinical Ph II |
|---|---|---|---|---|---|---|---|---|
|
IOMX-0675
|
LILRB1 / LILRB2 (ILT2 / ILT4)
Dual-targeting antibody
|
Solid tumors |
|
|
|
|
|
|
|
IOMX-0675 is a dual-targeting, best-in-class antibody, addressing a key immune-regulatory receptor family expressed on myeloid cells and other lymphoid immune cells, the LILR family. IOMX-0675 is a fully human, cross-specific, high-affinity ligand-blocking antibody that simultaneously neutralizes both, LILRB1 and LILRB2, while sparing LILRA1 and LILRA3, two closely related immune-activating receptor family members. The highly differentiated selectivity profile of IOMX-0675 unleashes the full anti-tumor potential by re-activating innate and adaptive immunity. 
|
||||||||
|
IOMX-0235
|
CCR9
Fc-enhanced antibody
|
Inflammatory bowel disease |
|
|
|
|
|
|
|
IOMX-0235 is a humanized, Fc-enhanced monoclonal antibody for the treatment of inflammatory bowel disease (Ulcerative Colitis & Crohn’s Disease). IOMX-0235 efficiently depletes CCR9-positive immune cells, key driver of the auto-inflammatory process underlying these conditions. IOMX-0235 has best-in-class potential for a clinically validated approach. An IOMX-0235 T-cell-engager is explored as potential innovative approach. 
|
||||||||
|
Discovery Programs
|
Undisclosed
Bispecifics & T cell engagers
|
Solid tumors |
|
|
|
|
|
|
|
iOmx is advancing multiple first-in-class and best-in-class discovery programs to expand its pipeline of next-generation immuno-oncology therapies. These include a tri-functional bispecific antibody synergistically blocking several immunosuppressive pathways, along with a series of T cell engager programs targeting novel, undisclosed tumor-specific antigens for the treatment of major solid tumor indications with high unmet medical need. 
|
||||||||
|
OMX-0407
|
SIKs & other oncology-relevant tyrosine kinases
Small molecule kinase inhibitor
|
Solid tumors |
|
|
|
|
|
|
|
a novel SIK inhibitor OMX-0407OMX-0407 is an orally available, first-in-class spectrum-selective inhibitor of SIK (salt-inducible kinase) and other oncology-relevant tyrosine kinases. The mode of action of OMX 0407 combines immune sensitization and modulation of the tumor microenvironment with direct tumor cell cycle arrest, thereby driving tumor eradication. Clinical development of OMX-0407 Continuation of clinical investigation in radiation-induced angiosarcoma, an ultra-rare indication, is under consideration in an investigator-led setting. 
|
||||||||
IOMX-0675
4
Target & Modality |
LILRB1 / LILRB2 (ILT2 / ILT4) Dual-targeting antibody |
Indications |
Solid tumors |
Phase |
IND Enabling |
IOMX-0675 is a dual-targeting, best-in-class antibody, addressing a key immune-regulatory receptor family expressed on myeloid cells and other lymphoid immune cells, the LILR family.
IOMX-0675 is a fully human, cross-specific, high-affinity ligand-blocking antibody that simultaneously neutralizes both, LILRB1 and LILRB2, while sparing LILRA1 and LILRA3, two closely related immune-activating receptor family members.
The highly differentiated selectivity profile of IOMX-0675 unleashes the full anti-tumor potential by re-activating innate and adaptive immunity.
IOMX-0235
3
Target & Modality |
CCR9 Fc-enhanced antibody |
Indications |
Inflammatory bowel disease |
Phase |
Lead Optimisation |
IOMX-0235 is a humanized, Fc-enhanced monoclonal antibody for the treatment of inflammatory bowel disease (Ulcerative Colitis & Crohn’s Disease). IOMX-0235 efficiently depletes CCR9-positive immune cells, key driver of the auto-inflammatory process underlying these conditions.
IOMX-0235 has best-in-class potential for a clinically validated approach.
An IOMX-0235 T-cell-engager is explored as potential innovative approach.
Discovery Programs
3
Target & Modality |
Undisclosed Bispecifics & T cell engagers |
Indications |
Solid tumors |
Phase |
Lead Optimisation |
iOmx is advancing multiple first-in-class and best-in-class discovery programs to expand its pipeline of next-generation immuno-oncology therapies. These include a tri-functional bispecific antibody synergistically blocking several immunosuppressive pathways, along with a series of T cell engager programs targeting novel, undisclosed tumor-specific antigens for the treatment of major solid tumor indications with high unmet medical need.
OMX-0407
6
Target & Modality |
SIKs & other oncology-relevant tyrosine kinases Small molecule kinase inhibitor |
Indications |
Solid tumors |
Phase |
Clinical Ph II |
a novel SIK inhibitor
OMX-0407
OMX-0407 is an orally available, first-in-class spectrum-selective inhibitor of SIK (salt-inducible kinase) and other oncology-relevant tyrosine kinases. The mode of action of OMX 0407 combines immune sensitization and modulation of the tumor microenvironment with direct tumor cell cycle arrest, thereby driving tumor eradication.
Clinical development of OMX-0407
A first-in-human dose-escalation trial of OMX-0407 monotherapy in patients with previously treated unresectable solid tumors has started in March 2023 (NCT05826600) has ended in early 2026 and the clinical development of OMX-0407 has been suspended for strategic reasons alone, i. e. not for safety reasons.
Continuation of clinical investigation in radiation-induced angiosarcoma, an ultra-rare indication, is under consideration in an investigator-led setting.